Breaking News Bar
updated: 1/4/2013 10:43 AM

Eli Lilly 2013 profit forecast tops expectations

hello
Success - Article sent! close
 
Associated Press

INDIANAPOLIS -- Eli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose U.S. patent protection for two more key products in the new year.

The Indianapolis company said Friday that it expects 2013 adjusted earnings of between $3.75 and $3.90 per share on $22.6 billion to $23.4 billion in revenue.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Analysts expect, on average, earnings of $3.72 per share on $22.87 billion in revenue, according to FactSet.

Lilly's revenue slipped last year after it lost U.S. patent protection for its all-time best selling drug, the antipsychotic Zyprexa. That exposed a drug that once topped $5 billion in annual revenue to cheaper generic competition.

This year, Lilly loses patent protection for its best-selling insulin, Humalog, in May and the antidepressant Cymbalta in December.

Cymbalta replaced Zyprexa as Lilly's top seller. Cymbalta and Humalog combined to generate about 44 percent of Lilly's roughly $8.7 billion in U.S. sales through the first nine months of 2012.

Lilly has said it will counter the revenue loss from the patent expirations by developing new drugs, cutting costs and depending on sales in foreign markets and developing countries. The drugmaker reiterated on Friday that it expects at least $3 billion in net income and revenue of at least $20 billion through 2014.

It also expects to keep paying shareholders a dividend and to complete a $1.5 billion share repurchase program this year.

Lilly also said Friday its forecast excludes a one-time benefit from the fiscal cliff deal. Company officials don't know yet whether that will be included in their adjusted earnings forecast.

The company reports fourth-quarter and 2012 results on Jan. 29.

Company shares climbed 53 cents to $49.72 Friday before trading started. The stock rose 19 percent in 2012 to close the year at $49.32.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here